Expression of E-cadherin in oral lichen planus

Du,Yong; Li,Haobo

doi:10.3892/etm.2015.2654

Expression of E-cadherin in oral lichen planus

Authors:
- Yong Du
- Haobo Li
View Affiliations

Affiliations: Department of Oral Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
Published online on: July 23, 2015 https://doi.org/10.3892/etm.2015.2654
Pages: 1544-1548

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral lichen planus (OLP) is a common lesion of the oral mucosa that can progress to cancer. E‑cadherin is involved in intercellular adherence and the pathogenesis, development and metastasis of tumors, and is considered to be an important indicator of tumor progression and prognosis. The aim of this study was to investigate the expression of E‑cadherin in OLP in order to elucidate its role in the pathogenesis and malignant transformation of OLP and provide evidence to support the early diagnosis and treatment of OLP with malignant potential. OLP specimens (n=52) and samples of normal oral mucosa (n=41) as the control were collected. Immunohistochemical staining was conducted to reveal the expression of E‑cadherin in the OLP samples and normal oral mucosa. It was observed that 25 of the 52 OLP specimens exhibited normal positive expression of E‑cadherin and 27 exhibited abnormal positive expression, corresponding to an abnormal positive rate of 51.92%. In the normal oral mucosa group, 39 of the 41 cases exhibited normal positive expression and 2 exhibited abnormal positive expression. The abnormal positive rate in the normal oral mucosa was 4.88%, which was significantly lower than that in the OLP group. The significantly elevated rate of abnormal positive expression of E‑cadherin in the OLP group indicates the involvement of E‑cadherin in the malignant transformation of OLP and supports the malignant potential of OLP.

View Figures

View References

1	Georgakopoulou EA, Achtari MD, Achtaris M, Foukas PG and Kotsinas A: Oral lichen planus as a preneoplastic inflammatory model. J Biomed Biotechnol. 2012:7596262012. View Article : Google Scholar : PubMed/NCBI
2	Bombeccari GP, Guzzi G, Tettamanti M, Gianni AB, Baj A, Pallotti F and Spadari F: Oral lichen planus and malignant transformation: A longitudinal cohort study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 112:328–334. 2011. View Article : Google Scholar : PubMed/NCBI
3	Shen ZY, Liu W, Feng JQ, Zhou HW and Zhou ZT: Squamous cell carcinoma development in previously diagnosed oral lichen planus: De novo or transformation? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 112:592–596. 2011. View Article : Google Scholar : PubMed/NCBI
4	Warnakulasuriya S, Johnson NW and Van der Waal I: Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 36:575–580. 2007. View Article : Google Scholar : PubMed/NCBI
5	Van der Waal I: Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 45:317–323. 2009. View Article : Google Scholar : PubMed/NCBI
6	Safadi RA, Al Jaber SZ, Hammad HM and Hamasha AA: Oral lichen planus shows higher expressions of tumor suppressor gene products of p53 and p21 compared to oral mucositis. An immunohistochemical study. Arch Oral Biol. 55:454–461. 2010. View Article : Google Scholar : PubMed/NCBI
7	Georgakopoulou EA, Troupis TG, Troupis G and Gorgoulis VG: Update of the cancer-associated molecular mechanisms in oral lichen planus, a disease with possible premalignant nature. J BUON. 16:613–616. 2011.PubMed/NCBI
8	Accurso BT, Warner BM, Knobloch TJ, Weghorst CM, Shumway BS, Allen CM and Kalmar JR: Allelic imbalance in oral lichen planus and assessment of its classification as a premalignant condition. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 112:359–366. 2011. View Article : Google Scholar : PubMed/NCBI
9	Andrews JL, Kim AC and Hens JR: The role and function of cadherins in the mammary gland. Breast Cancer Res. 14:2032012. View Article : Google Scholar : PubMed/NCBI
10	Rodriguez FJ, LewisTuffin LJ and Anastasiadis PZ: E-cadherin's dark side: Possible role in tumor progression. Biochim Biophys Acta. 1826:23–31. 2012.PubMed/NCBI
11	Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ and Sorensen PH: E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 67:3094–3105. 2007. View Article : Google Scholar : PubMed/NCBI
12	Tsalikidis C, Papachristou F, Pitiakoudis M, Asimakopoulos B, Trypsianis G, Bolanaki E, Syrigos KN and Simopoulos C: Soluble E-cadherin as a diagnostic and prognostic marker in gastric carcinoma. Folia Med (Plovdiv). 55:26–32. 2013.PubMed/NCBI
13	Wójcik-Krowiranda K, Forma E, Zaczek A, Bryś M, Anna MK and Bieńkiewicz A: Expression of E-cadherin and beta1-integrin mRNA in endometrial cancer. Ginekol Pol. 84:910–914. 2013.(In Polish). View Article : Google Scholar : PubMed/NCBI
14	Hashiguchi M, Ueno S, Sakoda M, Iino S, Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et al: Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI
15	Auvinen E, Carpen O, Korpela T, Ronty M, Vaheri A and Tarkkanen J: Altered expression of ezrin, E-cadherin and β-catenin in cervical neoplasia. Neoplasma. 60:56–61. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kyrodimou M, Andreadis D, Drougou A, Amanatiadou EP, Angelis L, Barbatis C, Epivatianos A and Vizirianakis IS: Desmoglein-3/γ-catenin and E-cadherin/β-catenin differential expression in oral leukoplakia and squamous cell carcinoma. Clin Oral Investig. 18:199–210. 2014. View Article : Google Scholar : PubMed/NCBI
17	Poomsawat S, Buajeeb W, Khovidhunkit SO and Punyasingh J: Overexpression of cdk4 and p16 in oral lichen planus supports the concept of premalignancy. J Oral Pathol Med. 40:294–299. 2011. View Article : Google Scholar : PubMed/NCBI
18	Supic G, Kozomara R, Jovic N, Zeljic K and Magic Z: Prognostic significance of tumor-related genes hypermethylation detected in cancer-free surgical margins of oral squamous cell carcinomas. Oral Oncol. 47:702–708. 2011. View Article : Google Scholar : PubMed/NCBI
19	Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT: Cox-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer. 89:2637–2645. 2000. View Article : Google Scholar : PubMed/NCBI
20	Regezi JA, Sciubba JJ and Jordan RCK: Oral Pathology: Clinical Pathologic Correlations. 6th. Elsevier Saunders; St. Louis, MO: 2012
21	Sun L, Feng J, Ma L, Liu W and Zhou Z: CD133 expression in oral lichen planus correlated with the risk for progression to oral squamous cell carcinoma. Ann Diagn Pathol. 17:486–489. 2013. View Article : Google Scholar : PubMed/NCBI
22	Sleeman JP and Thiery JP: SnapShot: The epithelial-mesenchymal transition. Cell. 145:162.e12011. View Article : Google Scholar : PubMed/NCBI
23	Wells A, Chao YL, Grahovac J, Wu Q and Lauffenburger DA: Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed). 16:815–837. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kolesnik AP, Shevchenko AI, Tumanskiĭ VA and Evseev AV: Effect of the intercellular adhesion molecule E-cadherin on the prognosis of non-small cell lung cancer. Arkh Patol. 75:30–33. 2013.(In Russian). PubMed/NCBI
25	Horne HN, Sherman ME, GarciaClosas M, Pharoah PD, Blows FM, Yang XR, Hewitt SM, Conway CM, Lissowska J, Brinton LA, et al: Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Res Treat. 143:181–187. 2014. View Article : Google Scholar : PubMed/NCBI
26	Sekar P, Bharti JN, Nigam JS, Sharma A and Soni PB: Evaluation of p53, HoxD10 and E-cadherin status in breast cancer and correlation with histological grade and other prognostic factors. J Oncol. 2014:7025272014. View Article : Google Scholar : PubMed/NCBI
27	Deep G, Jain AK, Ramteke A, Ting H, Vijendra KC, Gangar SC, Agarwal C and Agarwal R: SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin. Mol Cancer. 13:372014. View Article : Google Scholar : PubMed/NCBI
28	Nakagawa H, Hikiba Y, Hirata Y, FontBurgada J, Sakamoto K, Hayakawa Y, Taniguchi K, Umemura A, Kinoshita H, Sakitani K, et al: Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad Sci USA. 111:1090–1095. 2014. View Article : Google Scholar : PubMed/NCBI
29	Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
30	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kalluri R: EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Investig. 119:1417–1419. 2009. View Article : Google Scholar : PubMed/NCBI
32	von Zeidler SV, de Souza Botelho T, Mendonça EF and Batista AC: E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: A retrospective cohort study. BMC Cancer. 14:9722014. View Article : Google Scholar : PubMed/NCBI